H.C. Wainwright raised the firm’s price target on Connect Biopharma to $8 from $7 and keeps a Buy rating on the shares following the 2023 earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Triumphs with Rademikibart Trials
- Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
- Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
- Connect Biopharma initiated with a Buy at H.C. Wainwright